 |
Ben Butkus is senior editor of GenomeWeb's premium content and the editor of PCR Insider. He covers technologies and trends in PCR, qPCR, nucleic acid amplification, and sample prep. E-mail Ben Butkus or follow his GenomeWeb Twitter account at @PCRInsider. |
Epizyme Taps Roche to Develop Cobas 4800 CDx for Epizyme/Eisai Lymphoma Drug Candidate
January 10, 2013
Epizyme Taps Roche to Develop Cobas 4800 CDx for Epizyme/Eisai Lymphoma Drug Candidate
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Epizyme, Eisai, Roche Partner to Develop CDx for Investigational Lymphoma Treatment
January 7, 2013 / GenomeWeb Daily News - Dx Focus: Roche CT/NG Test Gets FDA OK; Pinpoint Genomics and BioReference Labs Launch Cancer Assays
February 2, 2012 / PCR Insider - Roche Launches Melanoma Companion Dx in EU After FDA OK Last Week
August 25, 2011 / PCR Insider - FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients
May 15, 2013 / GenomeWeb Daily News - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider